ES2194202T3 - Compuestos polimorfos. - Google Patents

Compuestos polimorfos.

Info

Publication number
ES2194202T3
ES2194202T3 ES97929654T ES97929654T ES2194202T3 ES 2194202 T3 ES2194202 T3 ES 2194202T3 ES 97929654 T ES97929654 T ES 97929654T ES 97929654 T ES97929654 T ES 97929654T ES 2194202 T3 ES2194202 T3 ES 2194202T3
Authority
ES
Spain
Prior art keywords
pct
fluvastatin sodium
fluvastatin
sodium form
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97929654T
Other languages
English (en)
Inventor
Karol Horvath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9602477A external-priority patent/SE9602477D0/xx
Priority claimed from SE9700751A external-priority patent/SE9700751D0/xx
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2194202T3 publication Critical patent/ES2194202T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA NUEVA FORMULA DE UN INHIBIDOR DE LA REDUCTASA HMG - COA, LA FLUVASTATINA, Y MAS ESPECIFICAMENTE A UNA FORMA ALTAMENTE CRISTALINA DE FLUVASTATINA SODIO, CONOCIDA COMO FLUVASTATINA SODIO FORMA B. LA INVENCION SE REFIERE IGUALMENTE A PROCESOS PARA LA PRODUCCION DE FLUVASTATINA SODIO FORMA B, A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN LA FLUVASTATINA SODIO EN FORMA B Y AL USO DE ESTE TIPO DE FLUVASTATINA SODIO EN TRATAMIENTOS MEDICOS.
ES97929654T 1996-06-24 1997-06-18 Compuestos polimorfos. Expired - Lifetime ES2194202T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9602477A SE9602477D0 (sv) 1996-06-24 1996-06-24 Polymorphic compounds
SE9700751A SE9700751D0 (sv) 1997-03-03 1997-03-03 Polymorphic compounds

Publications (1)

Publication Number Publication Date
ES2194202T3 true ES2194202T3 (es) 2003-11-16

Family

ID=26662685

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97929654T Expired - Lifetime ES2194202T3 (es) 1996-06-24 1997-06-18 Compuestos polimorfos.

Country Status (11)

Country Link
US (1) US6124340A (es)
EP (1) EP0907639B1 (es)
JP (2) JP4282092B2 (es)
AT (1) ATE234282T1 (es)
AU (1) AU3366297A (es)
CY (1) CY2461B1 (es)
DE (1) DE69719755T2 (es)
DK (1) DK0907639T3 (es)
ES (1) ES2194202T3 (es)
PT (1) PT907639E (es)
WO (1) WO1997049681A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902202D0 (sv) * 1999-06-10 1999-06-10 Astra Ab Production of aggregates
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
CN1210260C (zh) 2000-10-31 2005-07-13 西巴特殊化学品控股有限公司 氟伐他汀钠的晶形
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
JP4681808B2 (ja) * 2001-08-03 2011-05-11 チバ ホールディング インコーポレーテッド 結晶形
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE10316087A1 (de) * 2003-04-08 2004-11-11 Ratiopharm Gmbh Polymorphstabilisierung von Fluvastatin-Natrium in Pharmazeutischen Formulierungen
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7368581B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
JP2007524619A (ja) * 2003-06-18 2007-08-30 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム結晶型、その調製方法、これを含有する組成物、およびその使用法
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
EP1784504A2 (en) * 2004-07-21 2007-05-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Oatp-c gene c463a polymorphism underlies variable response of statin therapy
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
WO2006038219A1 (en) * 2004-10-05 2006-04-13 Biocon Limited Process for the preparation of amorphous fluvastatin sodium
US7795451B2 (en) * 2005-02-11 2010-09-14 Jubilant Organosys Limited Polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
CA2642180A1 (en) * 2006-02-27 2007-09-07 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium novel forms and preparation therof
ES2327668T3 (es) 2006-04-20 2009-11-02 F.I.S. Fabbrica Italiana Sintetici S.P.A. Procedimiento para la preparacion de sal sodica de fluvastatina.
CN101250153B (zh) * 2008-02-26 2013-09-18 深圳信立泰药业股份有限公司 一种制备氟伐他汀钠晶型的工艺
EP2419407B1 (en) * 2009-04-15 2012-11-14 Pharmathen S.A. Improved process for the preparation of fluvastatin and salts thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
AU570021B2 (en) * 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them

Also Published As

Publication number Publication date
WO1997049681A1 (en) 1997-12-31
AU3366297A (en) 1998-01-14
ATE234282T1 (de) 2003-03-15
CY2461B1 (en) 2005-06-03
JP2000512992A (ja) 2000-10-03
EP0907639B1 (en) 2003-03-12
DE69719755T2 (de) 2003-11-20
DK0907639T3 (da) 2003-06-23
JP2009149654A (ja) 2009-07-09
DE69719755D1 (de) 2003-04-17
EP0907639A1 (en) 1999-04-14
US6124340A (en) 2000-09-26
JP4282092B2 (ja) 2009-06-17
PT907639E (pt) 2003-06-30

Similar Documents

Publication Publication Date Title
ES2194202T3 (es) Compuestos polimorfos.
DE69831868D1 (en) Antithrombosemittel
DE69830504D1 (de) Antithrombotische mitteln
LU91751I2 (fr) Asenapin et ses dérivés pharmaceutiquement acceptables (SYCREST®)
AU2267395A (en) Benzofuran derivatives useful as inhibitors of bone resorption
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
ES2132415T3 (es) Nuevos derivados de 5-pirrolil-2-piridilmetilsulfinilbencimidazol.
AU2672995A (en) {a}-annelated pyrrole derivatives and pharmaceutical uses thereof
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
EP1019047A4 (en) ANTITHROMBOTIC AGENTS
BR0111102A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
DK0775113T3 (da) N-substituerede azabicycloheptan-derivater som neuroleptika osv.
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
ATE206917T1 (de) 2-phenyl-3-azoylbenzothiophene zur minderung des intraokularen drucks
ES2140683T3 (es) Procedimiento para preparar compuestos de benzopirano.
FI963166A (fi) Uusia merkaptoasetyyliamididisulfidijohdannaisia, jotka ovat käyttökelpoisia enkefalinaasin ja ACE:n inhibiittoreina
EE03488B1 (et) Meetod anhüdroekgoniini estrite valmistamiseks
DE69824410D1 (en) Antithrombosemittel